Sotalol
Treatment for Atrial Fibrillation
Typical Dosage: 80-160 mg twice daily
Effectiveness
68%
Safety Score
52%
Clinical Trials
40
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
52
DangerousModerateSafe
Treatment Details
Dosage Range
80-160 mg twice daily
Time to Effect
2-4 days
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$1,000
Side Effect Mgmt:$500
Total Annual:$1,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$40,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,931
Cost per Remission
$3,542
Comparison vs Metoprolol
Cost Difference
+$400/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
3 active trials recruiting for Sotalol in Atrial Fibrillation
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
NCT02347111RECRUITINGPHASE4
162 participants
INTERVENTIONAL
Chicago, United States +3 more
Started: Dec 31, 2020
Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
NCT04942834RECRUITINGNA
286 participants
INTERVENTIONAL
Fuzhou, China +16 more
Started: Oct 1, 2021
Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation
NCT06322017RECRUITINGNA
294 participants
INTERVENTIONAL
Nantes, France
Started: Apr 9, 2024
Completed Clinical Trials
10 completed trials for Sotalol in Atrial Fibrillation
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
NCT05279833COMPLETED
87.8K participants
OBSERVATIONAL
Chilly-Mazarin, France
Started: Sep 24, 2021
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
NCT04128878COMPLETED
12 participants
OBSERVATIONAL
Pittsburgh, United States
Started: May 1, 2019
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.
NCT00035451COMPLETEDPHASE3
658 participants
INTERVENTIONAL
Brussels, Belgium +128 more
Started: Feb 1, 2001
Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm
NCT00007605COMPLETEDPHASE3
706 participants
INTERVENTIONAL
Tucson, United States +27 more
Started: Apr 1, 1998
A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
NCT00408200COMPLETEDNA
110 participants
INTERVENTIONAL
Philadelphia, United States +1 more
Started: Nov 1, 2006
A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF
NCT02389218COMPLETEDPHASE4
13 participants
INTERVENTIONAL
Brussels, Belgium +2 more
Started: Mar 3, 2015
A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation
NCT00523978COMPLETEDPHASE3
245 participants
INTERVENTIONAL
Birmingham, United States +25 more
Started: Oct 1, 2006
Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)
NCT04991896COMPLETED
81 participants
OBSERVATIONAL
Chios, Greece
Started: Jan 1, 2020
Effectiveness Study of Atrial Fibrillation
NCT01856075COMPLETED
1.01K participants
OBSERVATIONAL
Bonn, Germany
Started: Oct 1, 2012
Using Smart Phone Technology in Detecting the Presence of Atrial Fibrillation
NCT02214069COMPLETED
60 participants
OBSERVATIONAL
Cleveland, United States
Started: Aug 1, 2014
Showing 20 of 40 total trials